 | • レポートコード：MRC2Q12-19130 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、不活性化インフルエンザウイルスワクチンのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 不活性化インフルエンザウイルスワクチンのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化インフルエンザウイルスワクチンの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 不活性化インフルエンザウイルスワクチンのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの不活性化インフルエンザウイルスワクチンの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の不活性化インフルエンザウイルスワクチンの売上および2028年までの予測に焦点を当てています。 不活性化インフルエンザウイルスワクチンのグローバル主要企業には、CSL、GSK、Sanofi Pasteur、Mylan、AstraZeneca、Pfizer、Johnson & Johnson、Jiangsu Jindik Biotechnology Co., Ltd、Beijing Kexing Biological Products Co., Ltd、Jiangsu Kangrun Biotechnology Co., Ltd、Hualan Bio Vaccines Co., Ltd、Dalian Yalifeng Biopharmaceutical Co., Ltd、Shanghai Institute of Biological Products Co., Ltd、Changchun Institute of Biological Products Co., Ltd、Lanzhou Institute of Biological Products Co., Ltd、Zhejiang Tian Yuan Biopharmaceutical Co., Ltd、Emmi Chengxin Biopharmaceutical Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 不活性化インフルエンザウイルスワクチン市場は、タイプとアプリケーションによって区分されます。世界の不活性化インフルエンザウイルスワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 全ウイルスワクチン、サブユニットワクチン 【アプリケーション別セグメント】 病院、診療所 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 不活性化インフルエンザウイルスワクチン製品概要 - タイプ別市場（全ウイルスワクチン、サブユニットワクチン） - アプリケーション別市場（病院、診療所） - 調査の目的 ・エグゼクティブサマリー - 世界の不活性化インフルエンザウイルスワクチン販売量予測2017-2028 - 世界の不活性化インフルエンザウイルスワクチン売上予測2017-2028 - 不活性化インフルエンザウイルスワクチンの地域別販売量 - 不活性化インフルエンザウイルスワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別不活性化インフルエンザウイルスワクチン販売量 - 主要メーカー別不活性化インフルエンザウイルスワクチン売上 - 主要メーカー別不活性化インフルエンザウイルスワクチン価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（全ウイルスワクチン、サブユニットワクチン） - 不活性化インフルエンザウイルスワクチンのタイプ別販売量 - 不活性化インフルエンザウイルスワクチンのタイプ別売上 - 不活性化インフルエンザウイルスワクチンのタイプ別価格 ・アプリケーション別市場規模（病院、診療所） - 不活性化インフルエンザウイルスワクチンのアプリケーション別販売量 - 不活性化インフルエンザウイルスワクチンのアプリケーション別売上 - 不活性化インフルエンザウイルスワクチンのアプリケーション別価格 ・北米市場 - 北米の不活性化インフルエンザウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化インフルエンザウイルスワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの不活性化インフルエンザウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化インフルエンザウイルスワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の不活性化インフルエンザウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化インフルエンザウイルスワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の不活性化インフルエンザウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化インフルエンザウイルスワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの不活性化インフルエンザウイルスワクチン市場規模（タイプ別、アプリケーション別） - 主要国別の不活性化インフルエンザウイルスワクチン市場規模（トルコ、サウジアラビア） ・企業情報 CSL、GSK、Sanofi Pasteur、Mylan、AstraZeneca、Pfizer、Johnson & Johnson、Jiangsu Jindik Biotechnology Co., Ltd、Beijing Kexing Biological Products Co., Ltd、Jiangsu Kangrun Biotechnology Co., Ltd、Hualan Bio Vaccines Co., Ltd、Dalian Yalifeng Biopharmaceutical Co., Ltd、Shanghai Institute of Biological Products Co., Ltd、Changchun Institute of Biological Products Co., Ltd、Lanzhou Institute of Biological Products Co., Ltd、Zhejiang Tian Yuan Biopharmaceutical Co., Ltd、Emmi Chengxin Biopharmaceutical Co., Ltd ・産業チェーン及び販売チャネル分析 - 不活性化インフルエンザウイルスワクチンの産業チェーン分析 - 不活性化インフルエンザウイルスワクチンの原材料 - 不活性化インフルエンザウイルスワクチンの生産プロセス - 不活性化インフルエンザウイルスワクチンの販売及びマーケティング - 不活性化インフルエンザウイルスワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 不活性化インフルエンザウイルスワクチンの産業動向 - 不活性化インフルエンザウイルスワクチンのマーケットドライバー - 不活性化インフルエンザウイルスワクチンの課題 - 不活性化インフルエンザウイルスワクチンの阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Inactivated Influenza Virus Vaccine include CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Inactivated Influenza Virus Vaccine manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Inactivated Influenza Virus Vaccine market. Further, it explains the major drivers and regional dynamics of the global Inactivated Influenza Virus Vaccine market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
CSL
GSK
Sanofi Pasteur
Mylan
AstraZeneca
Pfizer
Johnson & Johnson
Jiangsu Jindik Biotechnology Co., Ltd
Beijing Kexing Biological Products Co., Ltd
Jiangsu Kangrun Biotechnology Co., Ltd
Hualan Bio Vaccines Co., Ltd
Dalian Yalifeng Biopharmaceutical Co., Ltd
Shanghai Institute of Biological Products Co., Ltd
Changchun Institute of Biological Products Co., Ltd
Lanzhou Institute of Biological Products Co., Ltd
Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
Emmi Chengxin Biopharmaceutical Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Inactivated Influenza Virus Vaccine Segment by Type
Whole Virus Vaccine
Subunit Vaccine
Inactivated Influenza Virus Vaccine Segment by Application
Hospital
Clinic
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Inactivated Influenza Virus Vaccine market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer, Johnson & Johnson, Jiangsu Jindik Biotechnology Co., Ltd and Beijing Kexing Biological Products Co., Ltd, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Inactivated Influenza Virus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Influenza Virus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Inactivated Influenza Virus Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Whole Virus Vaccine
1.2.3 Subunit Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Inactivated Influenza Virus Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Inactivated Influenza Virus Vaccine Sales by Region
2.4.1 Global Inactivated Influenza Virus Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Inactivated Influenza Virus Vaccine by Region (2023-2028)
2.5 Global Inactivated Influenza Virus Vaccine Revenue by Region
2.5.1 Global Inactivated Influenza Virus Vaccine Revenue by Region (2017-2022)
2.5.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers
3.1.1 Global Top Inactivated Influenza Virus Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Influenza Virus Vaccine in 2021
3.2 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Influenza Virus Vaccine Revenue in 2021
3.3 Global Inactivated Influenza Virus Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Inactivated Influenza Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Inactivated Influenza Virus Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Inactivated Influenza Virus Vaccine Sales by Type
4.1.1 Global Inactivated Influenza Virus Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Inactivated Influenza Virus Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Inactivated Influenza Virus Vaccine Revenue by Type
4.2.1 Global Inactivated Influenza Virus Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Inactivated Influenza Virus Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Inactivated Influenza Virus Vaccine Price by Type
4.3.1 Global Inactivated Influenza Virus Vaccine Price by Type (2017-2022)
4.3.2 Global Inactivated Influenza Virus Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Inactivated Influenza Virus Vaccine Sales by Application
5.1.1 Global Inactivated Influenza Virus Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Inactivated Influenza Virus Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Inactivated Influenza Virus Vaccine Revenue by Application
5.2.1 Global Inactivated Influenza Virus Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Inactivated Influenza Virus Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Inactivated Influenza Virus Vaccine Price by Application
5.3.1 Global Inactivated Influenza Virus Vaccine Price by Application (2017-2022)
5.3.2 Global Inactivated Influenza Virus Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Inactivated Influenza Virus Vaccine Market Size by Type
6.1.1 North America Inactivated Influenza Virus Vaccine Sales by Type (2017-2028)
6.1.2 North America Inactivated Influenza Virus Vaccine Revenue by Type (2017-2028)
6.2 North America Inactivated Influenza Virus Vaccine Market Size by Application
6.2.1 North America Inactivated Influenza Virus Vaccine Sales by Application (2017-2028)
6.2.2 North America Inactivated Influenza Virus Vaccine Revenue by Application (2017-2028)
6.3 North America Inactivated Influenza Virus Vaccine Market Size by Country
6.3.1 North America Inactivated Influenza Virus Vaccine Sales by Country (2017-2028)
6.3.2 North America Inactivated Influenza Virus Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Inactivated Influenza Virus Vaccine Market Size by Type
7.1.1 Europe Inactivated Influenza Virus Vaccine Sales by Type (2017-2028)
7.1.2 Europe Inactivated Influenza Virus Vaccine Revenue by Type (2017-2028)
7.2 Europe Inactivated Influenza Virus Vaccine Market Size by Application
7.2.1 Europe Inactivated Influenza Virus Vaccine Sales by Application (2017-2028)
7.2.2 Europe Inactivated Influenza Virus Vaccine Revenue by Application (2017-2028)
7.3 Europe Inactivated Influenza Virus Vaccine Market Size by Country
7.3.1 Europe Inactivated Influenza Virus Vaccine Sales by Country (2017-2028)
7.3.2 Europe Inactivated Influenza Virus Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Type
8.1.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Application
8.2.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Inactivated Influenza Virus Vaccine Market Size by Region
8.3.1 Asia Pacific Inactivated Influenza Virus Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Inactivated Influenza Virus Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Inactivated Influenza Virus Vaccine Market Size by Type
9.1.1 Latin America Inactivated Influenza Virus Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Inactivated Influenza Virus Vaccine Revenue by Type (2017-2028)
9.2 Latin America Inactivated Influenza Virus Vaccine Market Size by Application
9.2.1 Latin America Inactivated Influenza Virus Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Inactivated Influenza Virus Vaccine Revenue by Application (2017-2028)
9.3 Latin America Inactivated Influenza Virus Vaccine Market Size by Country
9.3.1 Latin America Inactivated Influenza Virus Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Inactivated Influenza Virus Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Type
10.1.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Application
10.2.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Inactivated Influenza Virus Vaccine Market Size by Country
10.3.1 Middle East and Africa Inactivated Influenza Virus Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Inactivated Influenza Virus Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CSL
11.1.1 CSL Corporation Information
11.1.2 CSL Overview
11.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CSL Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Corporation Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Pasteur Recent Developments
11.4 Mylan
11.4.1 Mylan Corporation Information
11.4.2 Mylan Overview
11.4.3 Mylan Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Mylan Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Mylan Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Corporation Information
11.7.2 Johnson & Johnson Overview
11.7.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Johnson & Johnson Recent Developments
11.8 Jiangsu Jindik Biotechnology Co., Ltd
11.8.1 Jiangsu Jindik Biotechnology Co., Ltd Corporation Information
11.8.2 Jiangsu Jindik Biotechnology Co., Ltd Overview
11.8.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
11.9 Beijing Kexing Biological Products Co., Ltd
11.9.1 Beijing Kexing Biological Products Co., Ltd Corporation Information
11.9.2 Beijing Kexing Biological Products Co., Ltd Overview
11.9.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
11.10 Jiangsu Kangrun Biotechnology Co., Ltd
11.10.1 Jiangsu Kangrun Biotechnology Co., Ltd Corporation Information
11.10.2 Jiangsu Kangrun Biotechnology Co., Ltd Overview
11.10.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
11.11 Hualan Bio Vaccines Co., Ltd
11.11.1 Hualan Bio Vaccines Co., Ltd Corporation Information
11.11.2 Hualan Bio Vaccines Co., Ltd Overview
11.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
11.12 Dalian Yalifeng Biopharmaceutical Co., Ltd
11.12.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Corporation Information
11.12.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Overview
11.12.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
11.13 Shanghai Institute of Biological Products Co., Ltd
11.13.1 Shanghai Institute of Biological Products Co., Ltd Corporation Information
11.13.2 Shanghai Institute of Biological Products Co., Ltd Overview
11.13.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
11.14 Changchun Institute of Biological Products Co., Ltd
11.14.1 Changchun Institute of Biological Products Co., Ltd Corporation Information
11.14.2 Changchun Institute of Biological Products Co., Ltd Overview
11.14.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
11.15 Lanzhou Institute of Biological Products Co., Ltd
11.15.1 Lanzhou Institute of Biological Products Co., Ltd Corporation Information
11.15.2 Lanzhou Institute of Biological Products Co., Ltd Overview
11.15.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
11.16 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
11.16.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Corporation Information
11.16.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Overview
11.16.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
11.17 Emmi Chengxin Biopharmaceutical Co., Ltd
11.17.1 Emmi Chengxin Biopharmaceutical Co., Ltd Corporation Information
11.17.2 Emmi Chengxin Biopharmaceutical Co., Ltd Overview
11.17.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Inactivated Influenza Virus Vaccine Industry Chain Analysis
12.2 Inactivated Influenza Virus Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Influenza Virus Vaccine Production Mode & Process
12.4 Inactivated Influenza Virus Vaccine Sales and Marketing
12.4.1 Inactivated Influenza Virus Vaccine Sales Channels
12.4.2 Inactivated Influenza Virus Vaccine Distributors
12.5 Inactivated Influenza Virus Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Inactivated Influenza Virus Vaccine Industry Trends
13.2 Inactivated Influenza Virus Vaccine Market Drivers
13.3 Inactivated Influenza Virus Vaccine Market Challenges
13.4 Inactivated Influenza Virus Vaccine Market Restraints
14 Key Findings in The Global Inactivated Influenza Virus Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer